NASDAQ:PTX - Pernix Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.54 -0.03 (-5.26 %)
(As of 11/20/2018 04:00 PM ET)
Previous Close$0.57
Today's Range$0.52 - $0.58
52-Week Range$0.50 - $3.30
Volume108,300 shs
Average Volume130,332 shs
Market Capitalization$8.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.

Receive PTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PTX
Previous Symbol
CUSIP71426V10
Phone800-793-2145

Debt

Debt-to-Equity RatioN/A
Current Ratio1.08
Quick Ratio0.92

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.07 million
Price / Sales0.05
Cash FlowN/A
Price / CashN/A
Book Value($14.77) per share
Price / Book-0.04

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-77,140,000.00
Net Margins-59.70%
Return on EquityN/A
Return on Assets-41.61%

Miscellaneous

Employees171
Outstanding Shares14,510,000
Market Cap$8.46 million
OptionableOptionable

Pernix Therapeutics (NASDAQ:PTX) Frequently Asked Questions

What is Pernix Therapeutics' stock symbol?

Pernix Therapeutics trades on the NASDAQ under the ticker symbol "PTX."

How were Pernix Therapeutics' earnings last quarter?

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) issued its quarterly earnings results on Thursday, November, 8th. The specialty pharmaceutical company reported ($0.89) EPS for the quarter. The specialty pharmaceutical company earned $37.16 million during the quarter. View Pernix Therapeutics' Earnings History.

When is Pernix Therapeutics' next earnings date?

Pernix Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Pernix Therapeutics.

Has Pernix Therapeutics been receiving favorable news coverage?

News coverage about PTX stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pernix Therapeutics earned a news sentiment score of -1.2 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days.

Who are some of Pernix Therapeutics' key competitors?

Who are Pernix Therapeutics' key executives?

Pernix Therapeutics' management team includes the folowing people:
  • Mr. John Anthony Sedor, Chairman & CEO (Age 73)
  • Mr. Kenneth R. Pina Esq., Sr. VP, Chief Legal & Compliance Officer and Corp. Sec. (Age 59)
  • Mr. Angus W. Smith, Sr. VP, Chief Bus. Officer & Principal Financial Officer (Age 35)
  • Mr. Glenn Whaley, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 50)
  • Mr. Anthony M. Orrico, VP of Technical & Supply Operations

Who are Pernix Therapeutics' major shareholders?

Pernix Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (7.68%) and Aisling Capital LLC (1.51%). View Institutional Ownership Trends for Pernix Therapeutics.

Which institutional investors are selling Pernix Therapeutics stock?

PTX stock was sold by a variety of institutional investors in the last quarter, including Aisling Capital LLC. View Insider Buying and Selling for Pernix Therapeutics.

Which institutional investors are buying Pernix Therapeutics stock?

PTX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Pernix Therapeutics.

How do I buy shares of Pernix Therapeutics?

Shares of PTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pernix Therapeutics' stock price today?

One share of PTX stock can currently be purchased for approximately $0.54.

How big of a company is Pernix Therapeutics?

Pernix Therapeutics has a market capitalization of $8.46 million and generates $146.07 million in revenue each year. Pernix Therapeutics employs 171 workers across the globe.

What is Pernix Therapeutics' official website?

The official website for Pernix Therapeutics is http://www.pernixtx.com.

How can I contact Pernix Therapeutics?

Pernix Therapeutics' mailing address is 10 NORTH PARK PLACE SUITE 201, MORRISTOWN NJ, 07960. The specialty pharmaceutical company can be reached via phone at 800-793-2145 or via email at [email protected]


MarketBeat Community Rating for Pernix Therapeutics (NASDAQ PTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics and other stocks. Vote "Outperform" if you believe PTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Featured Article: What is Cost of Debt?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel